Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

X0202 SCHEDULE 13D/A 0001179313 XXXXXXXX LIVE 2 Common Stock, par value $0.0001 per share 04/29/2026 false 0001803599 20602D101 CONCENTRIX CORPORATION 39899 BALENTINE DRIVE NEWARK CA 94560 Priscilla Maters 32 22891717 c/o Groupe Bruxelles Lambert 24 avenue Marnix Brussels C9 1000 Y FINPAR VI SA OO N C9 0 38623.00 0 38623.00 38623.00 N 0.06 OO Y FINPAR V SA OO N C9 0 35964.00 0 35964.00 35964.00 N 0.06 OO Y Sapiens S.ar.l. OO N N4 0 2699080.00 0 2699080.00 2699080.00 N 4.42 OO Y GBL Verwaltung S.A. OO N N4 0 2699080.00 0 2699080.00 2699080.00 N 4.42 OO 0001179313 N Groupe Bruxelles Lambert OO N C9 0 2773667.00 0 2773667.00 2773667.00 N 4.55 OO Common Stock, par value $0.0001 per share CONCENTRIX CORPORATION 39899 BALENTINE DRIVE NEWARK CA 94560 This Amendment No. 2 (this "Amendment No. 2") amends and supplements the Schedule 13D, originally filed on October 5, 2023 (the "Original Schedule 13D") and Amendment No. 1, filed on January 30, 2026 ("Amendment No. 1" and, together with the Original Schedule 13D and this Amendment No. 2, the "Schedule 13D") relating to the common stock, par value $0.0001 per share (the "Common Stock"), of Concentrix Corporation (the "Issuer"), a Delaware corporation. Except as specifically provided herein, this Amendment No. 2 does not modify any of the information previously reported on the Schedule 13D. Capitalized terms not otherwise defined in this Amendment No. 2 shall have the same meanings ascribed thereto in the Schedule 13D. Items 5(a) - (c) and Item 5(e) of Schedule 13D are hereby amended and restated as follows: The responses of the Reporting Persons to rows (11) and (13) on the cover pages hereto is incorporated by reference herein. The Reporting Persons beneficially own an aggregate of 2,773,667 shares of Common Stock, representing 4.55% of the outstanding shares of Common Stock of the Issuer. Calculations of the percentage of the shares of Common Stock beneficially owned are based on an aggregate of 61,004,826 shares of Common Stock outstanding as of March 31, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended February 28, 2026, filed with the SEC on April 3, 2026. As of the date hereof, (i) FINPAR VI directly holds 38,623 shares of Common Stock; (ii) FINPAR V directly holds 35,964 shares of Common Stock; and (iii) Sapiens directly holds 2,699,080 shares of Common Stock. GBLV is the parent company of Sapiens, and therefore may be deemed to beneficially own the 2,699,080 shares of Common Stock directly held by the foregoing. GBL is the parent company of GBLV, FINPAR VI and FINPAR V and therefore may be deemed to beneficially own the 2,773,667 shares of Common Stock directly held by Sapiens, FINPAR VI and FINPAR V The Reporting Persons are also entitled to receive an additional 442,759 Earnout Shares if certain conditions set forth in the SPA occur, including the share price of Common Stock reaching $170.00 per share within seven years from the Closing Date (based on daily volume weighted average prices measured over a specified period). See "Put Option Share Purchase and Contribution Agreements" in Item 3 of the Original Schedule 13D. Neither the filing of this Schedule 13D nor any of its contents shall be deemed to constitute an admission that any Reporting Person is the beneficial owner of the Common Stock referred to herein for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. The responses of the Reporting Persons to rows (7) through (10) on the cover pages hereto and Item 5(a) hereof are incorporated by reference herein. On April 29, 2026, Sapiens sold 6,000,000 shares of Common Stock for $22.25 per share, in a block trade pursuant to Rule 144. Except for such transaction, the Reporting Persons have not effected any other transactions in Common Stock since the filing of Amendment No. 1. After giving effect to the April 29, 2026 sale by Sapiens, the Reporting Persons ceased to beneficially own 5% of the Common Stock and have no further beneficial ownership reporting obligations. FINPAR VI SA /s/ Priscilla Maters - /s/ Xavier Likin Priscilla Maters / Director - Xavier Likin / Director 05/01/2026 FINPAR V SA /s/ Priscilla Maters - /s/ Xavier Likin Priscilla Maters / Director - Xavier Likin / Director 05/01/2026 Sapiens S.ar.l. /s/ Priscilla Maters - /s/ Serge Saussoy Priscilla Maters / Director - Serge Saussoy / Director 05/01/2026 GBL Verwaltung S.A. /s/ Priscilla Maters - /s/ Serge Saussoy Priscilla Maters / Director - Serge Saussoy / Director 05/01/2026 Groupe Bruxelles Lambert /s/ Priscilla Maters - /s/ Xavier Likin Priscilla Maters / General Counsel - Xavier Likin / Chief Financial Officer 05/01/2026